B. Riley Downgrades Sucampo Pharmaceuticals (SCMP); Prestige Brands Holdings, Inc. (PBH) Had 9 Analysts Last Week

Among 13 analysts covering Sucampo Pharma (NASDAQ:SCMP), 10 have Buy rating, 0 Sell and 3 Hold. Therefore 77% are positive. Sucampo Pharma has $43 highest and $11.0 lowest target. $23.65’s average target is 31.24% above currents $18.02 stock price. Sucampo Pharma had 39 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) earned “Neutral” rating by Mizuho on Thursday, August 4. The company was maintained on Thursday, August 6 by WallachBeth Capital. Mizuho maintained Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) on Friday, December 8 with “Hold” rating. The firm earned “Buy” rating on Thursday, August 3 by Roth Capital. The firm earned “Buy” rating on Wednesday, August 2 by Maxim Group. The firm earned “Hold” rating on Wednesday, October 18 by Jefferies. Jefferies initiated Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) on Friday, November 20 with “Hold” rating. Mizuho upgraded the shares of SCMP in report on Wednesday, April 20 to “Buy” rating. TH Capital reinitiated the stock with “Buy” rating in Thursday, October 29 report. The firm has “Buy” rating given on Tuesday, February 9 by UBS.

Among 10 analysts covering Prestige Brands Holdings (NYSE:PBH), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Prestige Brands Holdings had 20 analyst reports since August 11, 2015 according to SRatingsIntel. As per Tuesday, September 19, the company rating was maintained by Jefferies. The rating was upgraded by William Blair on Monday, December 4 to “Outperform”. The rating was maintained by B. Riley & Co on Tuesday, December 27 with “Buy”. The firm has “Hold” rating by Zacks given on Tuesday, August 11. The company was reinitiated on Friday, June 2 by Jefferies. Piper Jaffray initiated Prestige Brands Holdings, Inc. (NYSE:PBH) on Friday, February 5 with “Overweight” rating. DA Davidson maintained Prestige Brands Holdings, Inc. (NYSE:PBH) on Thursday, October 12 with “Buy” rating. The rating was maintained by KeyBanc Capital Markets on Monday, October 16 with “Buy”. The firm earned “Hold” rating on Monday, August 14 by Jefferies. The company was upgraded on Monday, May 22 by Raymond James. See Prestige Brands Holdings, Inc. (NYSE:PBH) latest ratings:

04/12/2017 Broker: William Blair Old Rating: Market Perform New Rating: Outperform Upgrade
15/11/2017 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Outperform Upgrade
02/11/2017 Broker: Jefferies Rating: Hold New Target: $50.0 Maintain
16/10/2017 Broker: KeyBanc Capital Markets Rating: Buy New Target: $61.0 Maintain
12/10/2017 Broker: DA Davidson Rating: Buy New Target: $79.0 Maintain
19/09/2017 Broker: Jefferies Rating: Hold New Target: $54.0 Maintain
04/09/2017 Broker: KeyBanc Capital Markets Rating: Buy New Target: $61.0 Maintain
14/08/2017 Broker: Jefferies Rating: Hold New Target: $54.0 Maintain

Investors sentiment increased to 1.64 in 2017 Q3. Its up 0.34, from 1.3 in 2017Q2. It improved, as 19 investors sold Prestige Brands Holdings, Inc. shares while 57 reduced holdings. 32 funds opened positions while 93 raised stakes. 56.08 million shares or 5.89% more from 52.96 million shares in 2017Q2 were reported. Moreover, Thrivent Finance For Lutherans has 0% invested in Prestige Brands Holdings, Inc. (NYSE:PBH) for 11,310 shares. Virginia Retirement Et Al reported 47,200 shares stake. Ing Groep Nv, Netherlands-based fund reported 6,491 shares. Art Advsr Limited Liability Corp stated it has 12,597 shares or 0.03% of all its holdings. 47,649 are held by Legal & General Grp Public Limited. Panagora Asset Mngmt owns 73,980 shares. Global X Mngmt Ltd Liability Co holds 739 shares or 0% of its portfolio. Bessemer Grp Inc invested 0.01% in Prestige Brands Holdings, Inc. (NYSE:PBH). California Pub Employees Retirement Systems invested in 122,902 shares. Fuller Thaler Asset Inc, California-based fund reported 280 shares. Olstein Cap Mgmt L P has invested 0.39% in Prestige Brands Holdings, Inc. (NYSE:PBH). Ensemble Cap Ltd Liability Com owns 241,645 shares or 2.54% of their US portfolio. Nationwide Fund Advsr holds 129,070 shares or 0.03% of its portfolio. Citigroup stated it has 0% in Prestige Brands Holdings, Inc. (NYSE:PBH). Profund Advsr Ltd accumulated 9,438 shares.

The stock increased 0.37% or $0.165 during the last trading session, reaching $44.715. About 82,321 shares traded. Prestige Brands Holdings, Inc. (NYSE:PBH) has declined 8.57% since December 26, 2016 and is downtrending. It has underperformed by 25.27% the S&P500.

Prestige Brands Holdings, Inc., through its subsidiaries, markets, sells, makes, and distributes over-the-counter healthcare and household cleaning products in North America, Australia, and internationally. The company has market cap of $2.37 billion. It operates through North American OTC Healthcare, International OTC Healthcare, and Household Cleaning divisions. It has a 22.36 P/E ratio. The companyÂ’s OTC healthcare products include Chloraseptic sore throat treatments and mouth pain products, Clear Eyes eye care products, Compound W wart removers, Dramamine Non-Drowsy naturals, Efferdent denture cleansers, Luden's throat drops, BC and Goody's analgesic powders, Beano for gas prevention, Debrox for ear wax removal, and Gaviscon for upset stomach remedies.

The stock increased 6.03% or $1.02 during the last trading session, reaching $18.02. About 18.57 million shares traded or 1493.85% up from the average. Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has declined 5.30% since December 26, 2016 and is downtrending. It has underperformed by 22.00% the S&P500.

Investors sentiment increased to 1.65 in Q3 2017. Its up 0.32, from 1.33 in 2017Q2. It increased, as 14 investors sold Sucampo Pharmaceuticals, Inc. shares while 40 reduced holdings. 31 funds opened positions while 58 raised stakes. 29.83 million shares or 20.72% more from 24.71 million shares in 2017Q2 were reported. 6,604 were accumulated by Ls Invest Advisors Lc. Nationwide Fund Advsrs holds 32,008 shares or 0% of its portfolio. Federated Pa has invested 0% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Envestnet Asset Management Incorporated holds 14,387 shares or 0% of its portfolio. Bank Of America De holds 110,049 shares. New York-based New York State Teachers Retirement System has invested 0% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Wellington Management Grp Inc Limited Liability Partnership invested in 78,864 shares or 0% of the stock. Los Angeles Cap Mgmt And Equity reported 0% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Morgan Stanley owns 157,332 shares. Moreover, Deutsche Bancorp Ag has 0% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Schwab Charles reported 0% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Alps Advsrs Incorporated holds 0% or 45,847 shares in its portfolio. California State Teachers Retirement holds 38,483 shares. Price T Rowe Assoc Md has invested 0% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Virginia Retirement System Et Al stated it has 79,400 shares or 0.01% of all its holdings.

Since September 11, 2017, it had 0 insider purchases, and 3 selling transactions for $24.83 million activity. $12.00M worth of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) was sold by Ueno Ryuji. $825,000 worth of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) was sold by Kiener Peter A. Kuno Sachiko sold $12.00M worth of stock or 1.00M shares.

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally. The company has market cap of $836.54 million. The companyÂ’s marketed product includes AMITIZA , a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation in adult women (IBS-C), and opioid-induced constipation (OIC)in patients with chronic non-cancer related pain; and RESCULA (unoprostone isopropyl), a big potassium channel activator for the treatment of glaucoma and ocular hypertension. It currently has negative earnings. The Company’s product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis.

Analysts await Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) to report earnings on March, 14. They expect $0.34 EPS, down 50.00% or $0.34 from last year’s $0.68 per share. SCMP’s profit will be $15.78 million for 13.25 P/E if the $0.34 EPS becomes a reality. After $0.27 actual EPS reported by Sucampo Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 25.93% EPS growth.